An existing large scale analysis of variation of starting materials for Hematopoetic Stem Cell Therapies has highlighted the potential for deviations of practice in operator use of flow cytometers at single centre clinical facilities. This has potentially led to a variation of Quality Control data within cell therapy bioprocessing at distinct stages such as sample preparation, cytometer setup, data processing and results interpretation. A quantitative understanding of operator impact on results would significantly contribute to meeting and defining manufacturing quality control standards, as well as progressing regulatory guidance for measurement uncertainty when interpretation of results is required to sign off material for testing and release.

